Article
The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
Gene - 20 May 2022
Taheri Rana, Kazerouni Faranak, Mirfakhraei Reza, Kalbasi Saeid, Shahrokhi Seyedeh Zahra, Rahimipour Ali
Abstract excerpt
BACKGROUND AND AIMS: Among anti-diabetic medications, metformin has been proven to be the preferred initial pharmacologic agent for type 2 diabetes mellitus (T2DM) treatment. Despite its safety and efficacy, the response to metformin varies between individuals. Genetic variations, especially within genes involved in pharmacokinetics and pharmacodynamics of metformin (e.g SLC22A3), have been suggested to be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.